New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology;Neue AHA- und ACC-leitlinie zur risikoreduktion von herz-kreislauf- erkrankungen durch cholesterinsenkung. Stellungnahme der D•A•CH- Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e. V., der Österreichischen Atherosklerose Gesellschaft und der Arbeitsgruppe Lipide und Atherosklerose (AGLA) der Schweizer Gesellschaft für Kardiologie

Internist

Volumn 55, Issue 5, 2014, Pages 601-606

  Klose, G ^a   Beil, F U ^b   Dieplinger, H ^c   Von Eckardstein, A ^d   Foger B ^e   Gouni Berthold, I ^f   Koenig, W ^g,h   Kostner, G M ⁱ   Landmesser, U ^j   Laufs, U ^k   Leistikow, F ^l   Marz W ^i,m,n   Merkel, M ^o   Muller Wieland D ^o   Noll, G ^j   Parhofer, K G ^p   Paulweber, B ^q   Riesen, W ^r   Schaefer, J R ^s   Steinhagen Thiessen, E ^t,u   Steinmetz, A ^v   Toplak, H ⁱ   Wanner, C ^w   Windler, E ^x   more..

^a Praxis für Innere Medizin Gastroenterologie Kardiologie und Präventionsmedizin ^*  (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Abteilung fur Innere Medizin   (Austria)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h Dres Heigl Hettich and Partner Medizinisches Versorgungszentrum Kempten Allgäu   (Germany)

ⁱ MEDICAL UNIVERSITY OF GRAZ   (Austria)

^j Herzklinik Hirslanden   (Switzerland)

^k SAARLAND UNIVERSITY   (Germany)

^l Nierenzentrum Mannheim   (Germany)

^m MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

ⁿ SYNLAB ACADEMY   (Germany)

^o DEPARTMENT OF CARDIOLOGY   (Germany)

^p LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^q PARACELSUS MEDICAL UNIVERSITY   (Austria)

^r Private Universität im Fürstentum Liechtenstein UFL   (Liechtenstein)

^s UNIVERSITY HOSPITAL MARBURG   (Germany)

^t CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^u Evangelisches Geriatriezentrum   (Germany)

^v St Nikolaus Stiftshospital A   (Germany)

^w UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^x UNIVERSITY HEART CENTER HAMBURG   (Germany)

more..

Author keywords

Cardiovascular risk; Cholesterol; Guidelines; LDL; Statins

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; HUMAN; MEDICAL SOCIETY; PATIENT CARE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SCORING SYSTEM; SECONDARY PREVENTION; AUSTRIA; BLOOD; CARDIOLOGY; DIET THERAPY; HYPERCHOLESTEROLEMIA; RISK FACTOR; STANDARDS; SWITZERLAND;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AUSTRIA; CARDIOLOGY; DIET THERAPY; HUMANS; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SWITZERLAND;

EID: 84902374223     PISSN: 00209554     EISSN: 14321289     Source Type: Journal    
DOI: 10.1007/s00108-014-3492-z     Document Type: Review

References (25)

1. Reiner Z, Catapano AL, De Backer G et al (2011) ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769-1818
2. Perk J, De Backer G, Gohlke H et al (2012) European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 33:1635-1701
3. Stone NJ, Robinson J, Lichtenstein AH et al (2013) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (im Druck)
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
5. Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239 (Pubitemid 38924592)
6. Pedersen TR, Faergeman O, Kastelein JJ et al (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437-2445 (Pubitemid 41627921)
7. Zyriax BC, Boeing H, Windler E (2005) Nutrition is a powerful independent risk factor for coronary heart disease in women - The CORA study: a population-based case-control study. Eur J Clin Nutr 59:1201-1207 (Pubitemid 41508668)
8. Marz W, Scharnagl H, Winkler K et al (2004) Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 110:3068-3074 (Pubitemid 39492000)
9. DeGorter MK, Tirona RG, Schwarz UI et al (2013) Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet 6:400-408
10. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG et al (2001) Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158:183-193 (Pubitemid 32735483)
11. Scandinavian SSSG (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
12. Tonelli M, Wanner C (2013) Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med (im Druck)
13. Collins R, Armitage J, Parish S et al (2003) MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
14. Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670-1681
15. o A (1989) The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 129:687-702
16. Fried LP, Borhani NO, Enright P et al (1991) The cardiovascular health study: design and rationale. Ann Epidemiol 1:263-276
17. Friedman GD, Cutter GR, Donahue RP et al (1988) CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 41:1105-1116 (Pubitemid 19039041)
18. Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293-298
19. Wilson PW, D'Agostino RB, Levy D et al (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847 (Pubitemid 28213628)
20. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P (2001) Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286:180-187 (Pubitemid 32640849)
21. Ridker PM, Cook NR (2013) Statins: new American guidelines for prevention of cardiovascular disease. Lancet 382:1762-1765
22. Goff DC Jr, Lloyd-Jones DM, Bennett G et al (2013) 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation (im Druck)
23. Ference BA, Yoo W, Alesh I et al (2012) Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol 60:2631-2639
24. Wilkins JT, Ning H, Berry J et al (2012) Lifetime risk and years lived free of total cardiovascular disease. JAMA 308:1795-1801
25. Berry JD, Dyer A, Cai X et al (2012) Lifetime risks of cardiovascular disease. N Engl J Med 366:321-329